SOPHiA GENETICS SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports on the Annual General Meeting (AGM) held by SOPHiA GENETICS SA on June 18, 2026. The filing details the voting results on agenda items concerning the 2025 financial year, board composition, executive compensation, and amendments to the Articles of Association.
Key Financial Metrics
The filing provides specific data regarding the company's financial position for the year ended 2025:
- Net Loss (2025): CHF 52,825,053
- Accumulated Loss: CHF 403,784,733 (carried forward)
- Revenue, Cash Flow, and Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes and Governance Actions
Shareholders approved the following material items with high levels of support:
- Financial Statements: Approved the 2025 Management Report and Consolidated Financial Statements (99.57% in favor).
- Board Re-election: Re-elected the entire Board of Directors, including Jurgi Camblong as Chair, for terms ending in 2027. New director Ross Muken was elected.
- Compensation Caps: Approved maximum aggregate compensation limits for the upcoming period:
- Board of Directors: USD 1,942,600
- Executive Committee (Fixed): USD 3,606,907
- Executive Committee (Variable): USD 17,500,000
- Articles of Association: Approved amendments to increase conditional share capital for employee participation.
Outlook, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the company's accumulated losses. The most notable unusual item is the significant opposition to the Executive Committee's variable compensation package, which received 22.91% abstentions and 11.07% votes against, compared to higher approval rates for other items.
Investor Verification Checklist
- Verify the full 2025 Annual Report (Form 20-F) for detailed revenue, cash flow, and liquidity metrics not included in this summary.
- Review the specific terms of the conditional share capital increase approved in Item 10.
- Analyze the rationale behind the 22.91% abstention rate on executive variable compensation to assess shareholder sentiment.
- Confirm the impact of the accumulated loss of CHF 403.8 million on the company's capital structure and future financing needs.